Compare Mesoblast Limited (MESO) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Wendys Co — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Wendys Co trades at $7.75 (market cap $1.50B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Wendys Co pays a 7.13% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | WEN | |
|---|---|---|
Market Cap | $2.17B | $1.50B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $11.33 |
52-Week Low | $12.88 | $6.17 |
Enterprise Value | $2.17B | $5.31B |
Dividend Yield | — | 7.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Wendy's (WEN) trades at $7.805, up 0.58% with a bullish technical signal and recent earnings beats. The stock shows attractive valuation metrics with P/E of 10.07 and P/S of 0.68, though net margins have declined to 6.77%. Recent news highlights Project Fresh initiatives and China expansion plans, while the company maintains a $0.14 dividend payment scheduled for June 2026.
WEN presents a mixed outlook with strong valuation appeal and dividend yield offset by margin pressures and declining earnings. The stock's 28% monthly gain reflects retail investor enthusiasm, but fundamental challenges require careful monitoring of turnaround execution and competitive positioning in the crowded fast-food sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
